Pro-GRP has been identified as a biomarker for small-cell lung cancer (SCLC), an NE tissue differentiation disorder, and has been suggested to be useful in combination with NSE in monitoring the treatment of established SCLC [91]. This evidence concerns the gene ENO2 and small cell lung carcinoma.